Zobrazeno 1 - 4
of 4
pro vyhledávání: '"913"'
Autor:
Zetstra-van der Woude PA; Unit of PharmacoEpidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands., De Walle HE, Hoek A, Bos HJ, Boezen HM, Koppelman GH, de Jong-van den Berg LT, Scholtens S
Publikováno v:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2014 Oct; Vol. 23 (10), pp. 1059-65. Date of Electronic Publication: 2014 Jun 14.
Autor:
Hill GR; Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, P.O. Box 913, Dunedin, New Zealand. geraldine.hill@otago.ac.nz, Ashton J, Harrison-Woolrych M
Publikováno v:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2007 Nov; Vol. 16 (11), pp. 1217-26.
Autor:
Parkin L; Department of Preventive and Social Medicine, University of Otago, PO Box 913, Dunedin, New Zealand., Skegg DC, Herbison GP, Paul C
Publikováno v:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2003 Dec; Vol. 12 (8), pp. 647-52.
Autor:
Coulter DM; Centre for Adverse Reactions Monitoring, Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin, New Zealand. david.coulter@stonebow.otago.ac.nz
Publikováno v:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2001 Dec; Vol. 10 (7), pp. 663-7.